{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"161"},{"groupId":"OG001","value":"361"}]}],"title":"Hemoglobin (anemia), Any Grade Increase"},{"categories":[{"measurements":[{"groupId":"OG000","value":"46"},{"groupId":"OG001","value":"112"}]}],"title":"Hemoglobin (anemia), Increase to G1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"129"}]}],"title":"Hemoglobin (anemia), Increase to G2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"48"},{"groupId":"OG001","value":"114"}]}],"title":"Hemoglobin (anemia), Increase to G3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"6"}]}],"title":"Hemoglobin (anemia), Increase to G4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"136"},{"groupId":"OG001","value":"346"}]}],"title":"Lym. (lymphocytopenia), Any Grade Increase"},{"categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"43"}]}],"title":"Lym. (lymphocytopenia), Increase to G1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"80"}]}],"title":"Lym. (lymphocytopenia), Increase to G2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"48"},{"groupId":"OG001","value":"109"}]}],"title":"Lym. (lymphocytopenia), Increase to G3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"114"}]}],"title":"Lym. (lymphocytopenia), Increase to G4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"208"},{"groupId":"OG001","value":"394"}]}],"title":"Tot Neu. (neutropenia), Any Grade Increase"},{"categories":[{"measurements":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"106"}]}],"title":"Tot Neu. (neutropenia), Increase to G1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"53"},{"groupId":"OG001","value":"113"}]}],"title":"Tot Neu. (neutropenia), Increase to G2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"128"}]}],"title":"Tot Neu. (neutropenia), Increase to G3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"47"}]}],"title":"Tot Neu. (neutropenia), Increase to G4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"191"},{"groupId":"OG001","value":"391"}]}],"title":"WBC (leukocytopenia), Any Grade Increase"},{"categories":[{"measurements":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"113"}]}],"title":"WBC (leukocytopenia), Increase to G1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"145"}]}],"title":"WBC (leukocytopenia), Increase to G2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"110"}]}],"title":"WBC (leukocytopenia), Increase to G3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"23"}]}],"title":"WBC (leukocytopenia), Increase to G4"}],"denoms":[{"counts":[{"groupId":"OG000","value":"252"},{"groupId":"OG001","value":"506"}],"units":"Participants"}],"description":"Blood samples for the assessment of hematology parameters were taken at intervals throughout the study. Participants with the worst-case shift from BL during the DB Phase are reported, per severity grades by DAIDS, for levels of hemoglobin (low=anemia), lymphocytes (low=lymphocytopenia), total neutrophils (low=neutropenia), and white blood cells (low=leukocytopenia). Per the DAIDS toxicity table, grade ranges for each parameter are as follows: Grade (G) 1=mild; G2=moderate; G3=severe; G4=potentially life-threatening.","groups":[{"description":"Participants completing the OL Phase were administered matching placebo tablets QD in combination with antiviral therapy (peginterferon alfa-2b and ribavirin) for a duration of either 24 or 48 weeks (for participants with Genotype 2/3) or 48 weeks (for participants with Non-Genotype 2/3).","id":"OG000","title":"Placebo+Antiviral Therapy: DB Phase"},{"description":"Participants completing the OL Phase continued on the same dose of eltrombopag received in the OL Phase (dose that effectively raised platelets to \\>=100 Gi/L) in combination with antiviral therapy (peginterferon alfa-2b and ribavirin) for a duration of either 24 or 48 weeks (for participants with Genotype 2/3) or 48 weeks (for participants with Non-Genotype 2/3).","id":"OG001","title":"Eltrombopag+Antiviral Therapy: DB Phase"}],"paramType":"NUMBER","populationDescription":"Safety DB Population","reportingStatus":"POSTED","timeFrame":"From Baseline up to Week 48 or Week 72 (for participants with Genotype 2/3) or up to Week 72 (for participants with Non-Genotype 2/3)","title":"Number of Participants With the Indicated Shifts From BL in Severity Grades for for Hematology Parameters (Hemoglobin, Lymphocytes [Lym.], Total Neutrophils [Tot Neu.], and White Blood Cells [WBC]), Per DAIDS","type":"SECONDARY","unitOfMeasure":"participants"}